Stem Cell Therapeutics Markets

Date: February 23, 2009
Pages: 150
Price:
US$ 2,500.00
Publisher: Kalorama Information
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: SE102A9F739EN
Leaflet:

Download PDF Leaflet

Stem Cell Therapeutics Markets
Political and business events presage change for stem cell therapeutics, most notably the expected move by President Barack Obama to lift federal funding restrictions on stem-cell research. The U.S. Congress has also indicated a desire to move forward with stem cell research. The momentum in two branches of American government, along with scientific developments and the competition of world markets presages good market conditions for stem cell research.

With their ability to differentiate and become an ongoing source of cells that make up critical tissues and organs, stem cells have potential for new regenerative therapies and as new research tools for drug developers to test emerging therapies on diseased cells.

While companies have found opportunity outside the U.S., President Bush's seven year limitations on embryonic stem cell research in the U.S. has limited the U.S. market. Changes in U.S. policy should open up U.S. markets. For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the market. Kalorama Information has tackled that question in Stem Cells Therapeutics Markets. Kalorama analyst Alison Sahoo has built models to determine the best case and most likely case scenarios for therapeutic markets for stem cells in the coming years.

This report breaks down forecasted revenues and procedure volumes for stem cell technologies for these segments in the following disease areas:
  • Cardiovascular disease
  • Lung disease
  • Arthritis
  • Incontinence
  • Osteoporosis
  • Diabetes
  • Cancer
  • Orthopedics
  • Infertility
  • Alzheimer’s disease
  • Burns (severe)
  • Lupus
  • Parkinson’s disease
  • Liver failure
  • Multiple sclerosis
  • Critical limb ischemia
  • Crohn's disease
  • Sickle cell disease
  • Multiple myeloma
  • NH lymphoma
  • Leukemia
Ths report is the result of exclusive interviews with executives in the stem cell industry, a review of medical and company literature, government databases and publications. As part of this comprehensive analysis of stem cell markets, the following companies were profiled:
  • Aastrom Biosciences
  • Advanced Cell Technologies
  • Brainstorm Cell Therapeutics
  • Celegene
  • ES Cell International
  • Medistem
  • Neostem
  • Opexa Therapeutics
  • Osiris Therapeutics
  • Plureon
  • Regenetech
  • Revivicor
  • Stem Cell Sciences
  • StemLifeLine
  • ThermoGenesis
  • VetCell Bioscience
CHAPTER ONE: EXECUTIVE SUMMARY

Recent Developments
Introduction
Current Stem Cell Therapies
Developmental Stem Cell Therapies
Issues in Stem Cell Research
Stem Cell Forecasts
Market Forecast
The Promise of Stem Cells in Medical Treatment
Types of Stem Cells
Embryonic Stem Cells
Important Developments in ES Cell Research
Adult Stem Cells
Important Developments
Scope and Methodology

CHAPTER TWO: CURRENT STEM CELL THERAPIES

Cancer
Leukemia
Gene Therapy
Multiple Myeloma
Non-Hodgkin’s Lymphoma Noncancerous Diseases
Aplastic Anemia
Immunodeficiency
Lupus
Sickle Cell Disease
Other Conditions

CHAPTER THREE: DEVELOPMENTAL STEM CELL THERAPIES

Alzheimer’s Disease
Arthritis
Burns
Cancer
Cardiovascular Conditions
Critical Limb Ischemia
Crohn’s Disease
Diabetes
Incontinence
Infertility
Liver Failure
Lung Disease
Multiple Sclerosis
Orthopedics
Osteoporosis
Parkinson’s Disease
Sickle Cell Disease

CHAPTER FOUR: STEM CELL MARKET FORECASTS

Best Case
Forecasts By Disease Area
Alzheimer’s Disease
Arthritis
Burns
Cancer,
Cardiovascular Conditions
Critical Limb Ischemia
Crohn’s Disease
Diabetes,
Incontinence
Infertility,
Liver Failure
Lung Disease
Multiple Sclerosis
Orthopedics
Osteoporosis
Parkinson’s Disease
Sickle Cell Disease
Most Likely Case
Forecasts By Disease Area
Alzheimer’s Disease
Arthritis
Burns
Cancer,
Cardiovascular Conditions
Critical Limb Ischemia
Crohn’s Disease
Diabetes,
Incontinence
Infertility,
Liver Failure
Lung Disease
Multiple Sclerosis
Orthopedics
Osteoporosis
Parkinson’s Disease
Sickle Cell Disease

CHAPTER FIVE: COMPANY PROFILES

Aastrom Biosciences
Advanced Cell Technologies
Athersys
Brainstorm Cell Therapeutics
Celegene
ES Cell International
Medistem
MultiCell Technologies, Inc.
Neostem
Nephros Therapeutics, Inc.
Opexa Therapeutics
Osiris Therapeutics
Plureon
Regenetech
Revivicor
Stem Cell Sciences
ThermoGenesis
VetCell Bioscience


LIST OF EXHIBITS


CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-2: Stem Cell Therapeutics Market in $ Millions, 2007-2020

CHAPTER TWO: CURRENT STEM CELL THERAPIES

Table 2-1: Types of Leukemia, 2007

CHAPTER THREE: DEVELOPMENTAL STEM CELL THERAPIES

Table 3-1: Global Disease Populations Addressed by Potential Stem Cell Therapies, 2007
Table 3-2: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
Table 3-3: Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2007 and 2020
Table 3-4: Types and Features of Urinary Incontinence, 2007
Table 3-5: Types and Causes of Male Infertility, 2007
Table 3-6: Common Diseases of the Lungs, 2007

CHAPTER FOUR: STEM CELL MARKET FORECASTS

Table 4-1: Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2007
Table 4-2: Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020(Alzheimer’s Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn’s Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson’s Disease, Sickle Cell Disease)
Table 4-3: Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007 - 2020(Alzheimer’s Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn’s Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson’s Disease, Sickle Cell Disease)
Table 4-4: Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020(Alzheimer’s Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn’s Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson’s Disease, Sickle Cell Disease)
Table 4-5: Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007-2020(Alzheimer’s Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn’s Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson’s Disease, Sickle Cell Disease)

CHAPTER FIVE: COMPANY PROFILES

Table 5-1: Therapeutic Focus of Selected Stem Cell Therapeutics Companies, 2007
Skip to top


Ask Your Question

Stem Cell Therapeutics Markets
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: